Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.
about
A Rationale for Age-Adapted Immunosuppression in Organ TransplantationEffects of uridine diphosphate glucuronosyltransferase 2B7 and 1A7 pharmacogenomics and patient clinical parameters on steady-state mycophenolic acid pharmacokinetics in glomerulonephritisReasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.Nonlinear relationship between enteric-coated mycophenolate sodium dose and mycophenolic acid exposure in Han kidney transplantation recipientsPharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients.The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.Pharmacokinetics of mycophenolic acid in patients with lupus nephritis.Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis.Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoringUGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients.Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients.Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients.Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells.Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil.Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics of Immunosuppressants in Allogeneic Hematopoietic Cell Transplantation: Part II.Therapeutic drug monitoring of mycophenolic acid: does it improve patient outcome?Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.Safety considerations with mycophenolate sodium.High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients.Mycophenolate mofetil in the treatment of lupus nephritis.Mycophenolate pharmacokinetics and pharmacodynamics in belatacept treated renal allograft recipients - a pilot studyInfluence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis.Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes.Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.Limited sampling strategies for mycophenolic acid in solid organ transplantation: a systematic review.Pharmacogenetic influences on mycophenolate therapy.Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.Clinical pharmacokinetics and pharmacodynamics of mycophenolate in patients with autoimmune disease.How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients?Clinical mycophenolic acid monitoring in liver transplant recipients.Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients.Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis.Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis.The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.The pharmacokinetics and pharmacodynamics of mycophenolate mofetil in younger and elderly renal transplant recipients.Efficacy and safety of enteric-coated mycophenolate sodium in renal transplant patients with diabetes mellitus: post hoc analyses from three clinical trials.
P2860
Q28080954-FAC52690-38F7-400D-B548-96256C1A728EQ28285877-7BEA4AD9-4F33-499D-83F8-6A333CBEAC81Q33408239-D6DF4A91-97D3-4F5F-8963-4C1C7AEF73E5Q33683136-37768598-6AAB-4812-8915-7C0E4A4B8D81Q33764989-1315EC0B-798A-4D2A-81A0-B986C5D77710Q33944794-09A2A254-C862-46B7-B829-4A8825AA3520Q33984216-AFE05B7A-A1DE-46DA-9695-7AA65334260BQ34152549-9C8DB123-DDC4-4516-B3FD-5B34DA6B7F9CQ34858098-E3F0C8EF-C4D6-4484-AC4D-FD1CCE52AF80Q34984788-E6CFF6CA-6191-4DD1-8A8E-8C93E6184D49Q35619332-C15CFB86-A718-43A7-A06B-8D87FD067D99Q36025085-EAA702F8-4D7A-4D23-99C1-E02A8B75D82FQ36336060-9DC2458F-F211-458B-A162-DD92DEB66EB8Q36420758-14E5FCA6-F685-43E7-9F19-B3CB25FB3683Q36629233-7DE04016-2ECC-4F09-AC72-09BE86CD7E1BQ36728151-CE0C4C65-BD8C-4F88-BC6A-3ADAB1A0486BQ36777485-CEA0C1E8-5E40-4498-8C17-92D5858AB913Q36788423-14BEA1FC-12E9-424F-9470-8AAC2C074FF4Q36792638-9FAFBE64-E958-4F59-A9F7-1BFD3F6E63F0Q36905861-33A8783D-632C-406B-88E2-3BC26722C1AAQ37135382-9D6705FE-9F09-4061-AC78-EFB8F74D9334Q37290624-7220245E-230F-41D4-AC74-B1D079C0E949Q37299171-12143AE0-96BA-4558-B859-FC7B6FDE1454Q37423423-6E420AB1-AFAD-4D73-B200-B5354A78F751Q37438051-79340591-A39E-43B0-AF04-B17D0056AC26Q37441778-0BA4EDC2-ECBF-4250-8C60-507578BE69DFQ37581617-07880250-0DF4-4078-B3FB-31FFCA610DD4Q37710509-89728036-068A-48CD-A63F-ACD67F890F85Q37956717-3EBFBFCF-B231-4ED6-9F4F-AC91A11570CAQ38047203-F2351F3D-6093-491B-93DF-E2CE7305005DQ38087925-C1846FA8-583A-453A-9B79-B4382589160CQ38170321-4CDDAB99-89B7-4C0F-885E-2765EF669F6CQ38223136-972C3F3A-8DE0-4962-A69C-637C6CB13C65Q38242804-25E3B93D-166E-4353-B441-9BD8200A9D11Q38417581-64854F4A-170E-44A5-9FAB-EA89F3F35AA2Q38768108-E4C8ADF7-A49E-4ADD-9159-0AFF222E73F4Q39338374-82D5ABDD-03A9-4176-85DB-F5D53E39D073Q39778798-E4B984C7-3B8B-47A5-92F5-44FB05B41670Q40501892-A3EEB01E-0431-4961-A9C0-0EA204A3F62CQ42612278-2FFC9E7A-408D-44D7-A144-E283A3414449
P2860
Explaining variability in mycophenolic acid exposure to optimize mycophenolate mofetil dosing: a population pharmacokinetic meta-analysis of mycophenolic acid in renal transplant recipients.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Explaining variability in myco ...... n renal transplant recipients.
@en
Explaining variability in myco ...... n renal transplant recipients.
@nl
type
label
Explaining variability in myco ...... n renal transplant recipients.
@en
Explaining variability in myco ...... n renal transplant recipients.
@nl
prefLabel
Explaining variability in myco ...... n renal transplant recipients.
@en
Explaining variability in myco ...... n renal transplant recipients.
@nl
P2093
P356
P1476
Explaining variability in myco ...... in renal transplant recipients
@en
P2093
Mark D Pescovitz
Richard D Mamelok
Robert Gordon
Ron A A Mathot
Teun van Gelder
P304
P356
10.1681/ASN.2005101070
P577
2006-02-01T00:00:00Z